Objective:To investigate the expression and clinical significance of CENPF in renal clear cell carcinoma(KIRC).Methods:The UALCAN and HPA databases were applied to analyze the difference in expression of CENPF in KIRC compared with paracancerous tissue the relationship between CENPF gene and clinicopathological parameters and prognosis of KIRC patients were analyzed by the GEPIA database;the relationship between CENPF and immune infiltration level of KIRC were analyzed by the TIMER database;the UALCAN database was used to analyze the co-expression network of CENPF genes in TCGA KIRC patients,GO enrich-ment analysis and KEGG enrichment analysis were performed on the basis of the co-expression network.CCK-8,Transwell and clone formation assays were used to investigate the effect of CENPF down-regulated expression in renal cancer cell lines on the proliferation,migration and clone formation of ACHN and 786-O cells.Results:CENPF expression was significantly highly expressed in KIRC pa-tients.High CENPF expression was negatively correlated with overall survival(OS)and disease-free survival(DFS).The expression of CENPF in KIRC patients were significantly and positively correlated with tumor cell purity,macrophages,CD8+T cells,CD4+T cells,neutrophils and dendritic cells in tumor microenvironment.The correlation network analysis indicated that CENPF may be in-volved in the development of KIRC through the regulation of cell cycle,cell mitosis and DNA repair.In addition,CENPF mRNA ex-pression was also increased in renal cancer cell lines.CCK-8 assay showed that CENPF knockdown inhibited the proliferation of ACHN and 786-O cells.Transwell assay results indicated that CENPF knockdown suppressed the migration of KIRC cells.The results of cell clonal formation experiment showed that interference with CENPF gene expression inhibited the clonal formation ability of 786-O cells.Conclusion:This study suggests that CENPF plays a key role in the progression of KIRC.CENPF has prospective clinical sig-nificance as a prognostic indicator and potential target of KIRC.

Lung cancer associated with cystic airspaces (LCCA) is a type of lung cancer characterized by the presence of cystic cavities in or around the tumor on imaging. Due to its high potential for misdiagnosis or underdiagnosis, the prognosis of LCCA patients is poor, necessitating further large-scale clinical studies to elucidate its characteristics. Currently, four imaging classification systems exist, and there has been a progressive increase in attention towards LCCA, particularly with regard to the study of its imaging features. The results indicate a correlation between the pathological features and imaging findings of LCCA; however, research on driver gene mutations and molecular subtyping associated with lung cancer remains insufficient. Due to the challenges associated with early diagnosis and the poorer prognosis compared to general types of lung cancer, this paper comprehensively reviews the research progress on LCCA, including its definition, etiology, pathogenesis, imaging features, histological and pathological features, treatment, and prognosis, aiming to serve as a valuable resource for clinical decision-making.
.
Humans ; Lung Neoplasms/genetics* ; Tomography, X-Ray Computed/methods* ; Prognosis

Escherichia coli is a highly adaptable opportunistic pathogen bacterium that can form biofilms on the surface of implants and generates persistent cells,leading to life-threatening infections that are difficult to treat with antibiotics alone.Therefore,there is a need for an effective E.coli biofilm inhibitor to combat this public health threat.Indole is a novel quorum-sensing signaling molecule of E.coli discovered in recent years,which is of great significance in regulating bacterial growth and biofilm formation,and is a potential target for future research on new anti-biofilm preparations.This article reviews the research progress on the formation of Escherichia coli biofilms,the microbial metabolism of indole and its regulation of Escherichia coli biofilm formation,in order to provide information for clinical treatment and drug development.